title: Evaluating prethrombotic state in lung cancer using molecular markers.
abstract: Clotting abnormalities are well-recognized complications that occur with high frequency in patients suffering from underlying malignant diseases. New and highly sensitive molecular markers of hemostasis, thrombin-antithrombin III complex (TAT III), D-dimer fragments (DD), and plasmin-alpha 2-antiplasmin complex (PIC) were measured in 58 consecutive lung cancer patients. Significant elevation in the blood concentrations of DD, PIC, and TAT was found in lung cancer patients, with either extensive or limited disease compared with values obtained in a healthy control group and in another group of patients with chronic obstructive pulmonary disease. Patients with distant metastasis exhibited significantly higher levels of these parameters as compared to those without metastasis. These data indicated that there was a subclinical activation of blood coagulation and fibrinolysis in lung cancer from the early clinical stages of the disease. In addition, there appeared to be different levels of clotting activation according to histologic type of tumor and response to chemotherapy.
authors.affiliation: Third Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
authors.forename: E C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: O
authors.initials: O
authors.lastname: Taguchi
authors.forename: T
authors.initials: T
authors.lastname: Yamakami
authors.forename: M
authors.initials: M
authors.lastname: Machishi
authors.forename: H
authors.initials: H
authors.lastname: Ibata
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000556:secondary; D000933:Antifibrinolytic Agents / Q000097:blood*; D000990:Antithrombin III / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005341:Fibrinolysin / Q000032:analysis*; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010447:Peptide Hydrolases / Q000032:analysis*; D012074:Remission Induction; D013927:Thrombosis / Q000097:blood; D000979:alpha-2-Antiplasmin / Q000032:analysis*
chemical_list: D000933:Antifibrinolytic Agents; D014408:Biomarkers, Tumor; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin; D002945:Cisplatin